



Post Authorisation Assessments

Amflee 50 mg Spot-on Solution for Cats Vm 01656/4086

10 January 2025	Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible. (GB and NI).
05 November 2024	Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex. (NI).
24 December 2021	Minor change in the manufacturing process of the finished product.
18 August 2021	Change of specification(s) of a former non Pharmacopoeial active substance to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State. Deletion of manufacturing site for an active substance.
21 December 2020	Increase in the shelf-life of the finished product as packaged for sale, from 30 months to 36 months.
03 March 2020	Renewal – UK as CMS.
08 March 2019	Change in the contact details of the QPPV of an existing pharmacovigilance system as described in the DDPS.
09 March 2018	Change in RMS from UK to DE.
22 February 2018	Change in contact details for local representative.
03 March 2016	Addition of a site of manufacture for the active substance